MedTrace Logo

Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty

NCT01267279 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2018-12-19

Study results available
· View outcomes & findings →

Summary

In a randomized, double-blind trial, BMD of the operated proximal femur after total hip replacement measured by dual-energy x-ray absorptiometry (DXA) were compared for up to two years in patients receiving IV ZOL 5 mg infusion (n = 27) or placebo (IV saline infusion; n = 24) at two weeks and one year after surgery.

Conditions

Interventions

DRUG

Zoledronic acid

Zoledronic acid per protocol

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Spokane Joint Replacement Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2014-12-31
Completion
2014-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01267279 on ClinicalTrials.gov